Your browser doesn't support javascript.
loading
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti, Abhishek; Qiao, Wei; Sasaki, Koji; Ravandi, Farhad; Kadia, Tapan M; Jabbour, Elias J; Daver, Naval G; Borthakur, Gautam; Garcia-Manero, Guillermo; Pierce, Sherry A; Montalbano, Kathryn S; Pemmaraju, Naveen; Naqvi, Kiran; Ohanian, Maro; Short, Nicholas J; Alvarado, Yesid; Takahashi, Koichi; Yilmaz, Musa; Jain, Nitin; Kornblau, Steven M; Andreeff, Michael; Bose, Prithviraj; Ferrajoli, Alessandra; Issa, Ghayas C; Masarova, Lucia; Thompson, Philip A; Rausch, Caitlin R; Ning, Jing; Kantarjian, Hagop M; DiNardo, Courtney D; Konopleva, Marina Y.
Afiliação
  • Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Qiao W; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sasaki K; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pierce SA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Montalbano KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Naqvi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kornblau SM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bose P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Thompson PA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rausch CR; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ning J; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kantarjian HM; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 96(3): 282-291, 2021 03 01.
Article em En | MEDLINE | ID: mdl-33264443
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos